COnsultation system of Nationwide oncology medical NEeds with online Communication Tool in Clinical Trials CONNECT-ClinicalTrials

COnsultation system of Nationwide oncology medical NEeds with online Communication Tool in Clinical Trials CONNECT-ClinicalTrials - CONNECT-ClinicalTrials

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056850

Enrollment

170

Registered

2025-01-28

Start date

2025-02-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients consulted through this system will be the target population.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Percentage of patients who were connected to a clinical trial within 3 months of referral, among patients who were referred to the National Cancer Center Hospital for clinical trials through the Join-based inquiry system.	—

Secondary

Measure	Time frame
1) Percentage of patients referred through this system who were referred to the National Cancer Center Hospital for clinical trials who were connected to a clinical trial proposed at the time of referral within 3 months after referral 2) Percentage of patients referred through this system who were referred to the National Cancer Center Hospital for clinical trials who were not connected to a clinical trial within 3 months after referral 3) Of the patients referred through this system and referred to the National Cancer Center Hospital for clinical trials, the percentage of patients who were connected to clinical trials (clinical trials and other clinical trials), the percentage of patients who were connected to clinical trials proposed at the time of referral, and the percentage of patients who were not connected to clinical trials 4) Number of patients referred through the system who participated in clinical trials and other clinical trials, phase of participating clinical trials, names of clinical trials (investigational drugs), patient age, gender, cancer type, number of treatment regimens, and other clinical information 5) Percentage of patients referred through the system who continued treatment at the referring hospital, and breakdown of these patients (those who visited the National Cancer Center Hospital, those who did not visit the hospital, and those who did not participate in proposed clinical trials) 6) Number of patients who received recommended treatment based on cancer genome profiling tests among patients referred through the system and who participated in clinical trials 7) Total number of patients whose clinical information was registered in the system, breakdown of cancer types 8) The period of review within the National Cancer Center Hospital (the number of days from inquiry to response on the system, converted into business days) 9) The number of cases reviewed in one week within the National Cancer Center Hospital	—

Measure

Time frame

1) Percentage of patients referred through this system who were referred to the National Cancer Center Hospital for clinical trials who were connected to a clinical trial proposed at the time of referral within 3 months after referral 2) Percentage of patients referred through this system who were referred to the National Cancer Center Hospital for clinical trials who were not connected to a clinical trial within 3 months after referral 3) Of the patients referred through this system and referred to the National Cancer Center Hospital for clinical trials, the percentage of patients who were connected to clinical trials (clinical trials and other clinical trials), the percentage of patients who were connected to clinical trials proposed at the time of referral, and the percentage of patients who were not connected to clinical trials 4) Number of patients referred through the system who participated in clinical trials and other clinical trials, phase of participating clinical trials, names of clinical trials (investigational drugs), patient age, gender, cancer type, number of treatment regimens, and other clinical information 5) Percentage of patients referred through the system who continued treatment at the referring hospital, and breakdown of these patients (those who visited the National Cancer Center Hospital, those who did not visit the hospital, and those who did not participate in proposed clinical trials) 6) Number of patients who received recommended treatment based on cancer genome profiling tests among patients referred through the system and who participated in clinical trials 7) Total number of patients whose clinical information was registered in the system, breakdown of cancer types 8) The period of review within the National Cancer Center Hospital (the number of days from inquiry to response on the system, converted into business days) 9) The number of cases reviewed in one week within the National Cancer Center Hospital

—

Countries

Japan

Contacts

Public ContactTatsunori Shimoi

National Cancer Center Hospital Department of Medical Oncology

tshimoi@ncc.go.jp0335422511

Outcome results